logo
Sign In
Farxiga vs. GlyxambiBerinert vs. CinryzeEmgality vs. QuliptaFarxiga vs. InvokanaFirazyr vs. SajazirGlyxambi vs. InvokanaInvokamet vs. SynjardyOpzelura vs. DupixentOrencia vs. RinvoqQulipta vs. VyeptiStelara vs. TremfyaSynjardy vs. VictozaTaltz vs. BimzelxVyepti vs. Nurtec ODTView all Comparisons
ADHD drugsAnxiety drugsAsthma drugsAtopic dermatitis drugsDepression drugsHeart failure drugsHypertension drugsLymphoma drugsOsteoarthritis drugsRheumatoid arthritis drugsRosacea drugsSchizophrenia drugsType 2 Diabetes drugsView all Indications
Bayer drugsAbbVie drugsAstraZeneca drugsEli Lilly and Company drugsGenetech drugsGlaxoSmithKline (GSK) drugsNovartis drugsPfizer drugsTakeda Pharmaceuticals drugsTeva Pharmaceuticals drugsAmgen drugsView all Manufacturers
Beta-Adrenergic BlockerAngiotensin Converting Enzyme InhibitorAngiotensin 2 Receptor BlockerCalcium Channel BlockerDiureticsHMG-CoA Reductase InhibitorProton Pump InhibitorSelective Serotonin Reuptake InhibitorNorepinephrine Reuptake InhibitorBenzodiazepinesOpioid AgonistsNonsteroidal Anti-inflammatory DrugsAntiepileptic AgentsAntipsychoticsAntihistaminesView all Classes
Wegovy®Ozempic®Mounjaro®Zepbound®Jardiance®Farxiga®Dupixent®Trulicity®Lyrica®Lipitor®Effexor®Concerta®Depakote®Trintellix®Rexulti®Rinvoq®Verzenio®Taltz®
For ProvidersRequest DemoJoin Research Panel
For BusinessHCP ChannelCommercial O/SEngageMarketplaceOneHubInsight
Tools & MorePrescribing InfoCoverageSavingsPatient ResourcesA-Z IndicationsCompare Drugs
CompanyAboutInsightsCareersContactSecurity
Legit Script Certified
Get the latest insights in your inbox
Follow us
Legit Script Certified
  • Terms and Conditions
  • Privacy Policy
  • © 2025 PrescriberPoint. All Rights Reserved.
  • Medications for Arthritis Psoriatic

    FiltersReset Filters
    70 results
    • abrilada

      (adalimumab-afzb)
      Pfizer Laboratories Div Pfizer Inc
      Usage: ABRILADA is indicated for the treatment of various conditions, including rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, ulcerative colitis, moderate to severe chronic plaque psoriasis, hidradenitis suppurativa, and non-infectious uveitis in adults and certain pediatric patients.
    • abrilada

      (adalimumab-afzb)
      Pfizer Laboratories Div Pfizer Inc
      Usage: ABRILADA is indicated for treating moderately to severely active rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, ulcerative colitis, plaque psoriasis, hidradenitis suppurativa, and non-infectious uveitis in adults and pediatric patients.
    • acthar

      (Repository Corticotropin)
      Mallinckrodt ARD LLC
      Usage: Acthar Gel is indicated for treating infantile spasms in infants, acute exacerbations of multiple sclerosis in adults, and various rheumatic disorders. It is also used for collagen diseases, severe dermatologic conditions, allergic states, specific ophthalmic and respiratory diseases, and to manage proteinuria in nephrotic syndrome.
    • adalimumab

      (adalimumab-fkjp)
      Biocon Biologics Inc
      Usage: Adalimumab-fkjp is indicated for treating moderate to severe rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn’s disease, ulcerative colitis, plaque psoriasis, hidradenitis suppurativa, and non-infectious uveitis in adults and pediatric patients (ages vary by condition).
    • adalimumab-ryvk

      (adalimumab-ryvk)
      Quallent Pharmaceuticals Health LLC
      Usage: Adalimumab-ryvk is indicated for the treatment of moderately to severely active rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn’s disease, ulcerative colitis, chronic plaque psoriasis, hidradenitis suppurativa, and non-infectious uveitis in patients ages 2 and older.
    • amjevita

      (adalimumab-atto)
      Optum Health Solutions (Ireland) Limited
      Usage: AMJEVITA is indicated for various autoimmune conditions, including rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, ulcerative colitis, chronic plaque psoriasis, hidradenitis suppurativa, and non-infectious uveitis, to reduce symptoms and improve functionality.
    • bimzelx

      (bimekizumab)
      UCB, Inc.
      Usage: BIMZELX is used to treat moderate to severe plaque psoriasis, active psoriatic arthritis, active non-radiographic axial spondyloarthritis with inflammation, active ankylosing spondylitis, and moderate to severe hidradenitis suppurativa in adults who qualify for systemic therapy or phototherapy.
    • cimzia

      (certolizumab pegol)
      UCB, Inc.
      Usage: CIMZIA is indicated for treating moderately to severely active Crohn's disease, rheumatoid arthritis, polyarticular juvenile idiopathic arthritis in patients aged 2 and older, psoriatic arthritis, ankylosing spondylitis, non-radiographic axial spondyloarthritis, and moderate-to-severe plaque psoriasis in adults.
    • cosentyx

      (secukinumab)
      Novartis Pharmaceuticals Corporation
      Usage: COSENTYX is indicated for treating moderate to severe plaque psoriasis in patients 6 years and older, active psoriatic arthritis from age 2, adult ankylosing spondylitis, active non-radiographic axial spondyloarthritis, active enthesitis-related arthritis in patients 4 years and older, and moderate to severe hidradenitis suppurativa in adults.
    • cyltezo

      (adalimumab-adbm)
      Boehringer Ingelheim Pharmaceuticals, Inc.
      Usage: CYLTEZO is indicated for treating moderately to severely active rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn’s disease, ulcerative colitis, chronic plaque psoriasis, hidradenitis suppurativa, and non-infectious uveitis in adults and pediatric patients aged 2 and older.
    • ...